Kyeonghwan Kim
Overview
Explore the profile of Kyeonghwan Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoon S, Yun Kim H, Park S, Cha M, Kim K, Lee S, et al.
Angew Chem Int Ed Engl
. 2024 Sep;
63(51):e202411942.
PMID: 39314129
Comprehending early amyloidogenesis is essential for the development of effective therapeutic strategies. In tauopathies like Alzheimer's disease (AD), the abnormal accumulation of tau protein is initiated by pathological tau seeds....
2.
Park S, Shin J, Kim K, Kim D, Lee W, Lee J, et al.
ACS Pharmacol Transl Sci
. 2024 Sep;
7(9):2650-2661.
PMID: 39296253
Aggregation of misfolded amyloid-β (Aβ) and hyperphosphorylated tau proteins to plaques and tangles, respectively, is the major drug target of Alzheimer's disease (AD), as the former is an onset biomarker...
3.
An J, Kim K, Lim H, Yun Kim H, Shin J, Park I, et al.
Nat Commun
. 2024 Feb;
15(1):1004.
PMID: 38307843
Amyloid-β (Aβ) oligomers are implicated in the onset of Alzheimer's disease (AD). Herein, quinoline-derived half-curcumin-dioxaborine (Q-OB) fluorescent probe was designed for detecting Aβ oligomers by finely tailoring the hydrophobicity of...
4.
Cha M, Dagar A, Lee S, Cho I, Lee D, Kim K, et al.
ACS Chem Neurosci
. 2023 Aug;
14(17):3025-3034.
PMID: 37552840
Abnormal assembly of amyloid β (Aβ) in the brain is implicated in Alzheimer's disease (AD) and is associated with cognitive impairments. Since Aβ accumulation occurs in advance of the onset...
5.
Lee S, Dagar A, Cho I, Kim K, Park I, Yoon S, et al.
ACS Chem Neurosci
. 2023 May;
14(11):2016-2026.
PMID: 37171100
Cerebral amyloid-β (Aβ) deposition is a representative hallmark of Alzheimer's disease (AD). Development of Aβ-clearing small molecules could be an advantageous therapeutic strategy for Aβ clearance considering the advantages in...
6.
Lee H, Yoon S, Lee J, Park K, Jung Y, Cho I, et al.
Alzheimers Res Ther
. 2022 Nov;
14(1):177.
PMID: 36443837
Background: Aggregated amyloid-β (Aβ) is considered a pathogenic initiator of Alzheimer's disease (AD), in strong association with tau hyperphosphorylation, neuroinflammation, synaptic dysfunction, and cognitive decline. As the removal of amyloid...
7.
Lee H, Baek S, Cha M, Yang S, Cho I, Shin H, et al.
Angew Chem Int Ed Engl
. 2022 Oct;
62(7):e202210209.
PMID: 36316282
Amyloid-β (Aβ) in the form of neurotoxic aggregates is regarded as the main pathological initiator and key therapeutic target of Alzheimer's disease. However, anti-Aβ drug development has been impeded by...
8.
Kim K, Lee J, Kim S, Lee S, Lee D, Yun Kim H, et al.
RSC Med Chem
. 2021 Nov;
12(11):1926-1934.
PMID: 34825188
Abnormal deposition of amyloid-β (Aβ) is a major biomarker that is often used to diagnose Alzheimer's disease (AD). The Aβ plaque levels in the cortex and hippocampus are measured by...
9.
Kim D, Lee J, Yun Kim H, Shin J, Kim K, Lee S, et al.
PLoS One
. 2021 Apr;
16(4):e0250194.
PMID: 33831134
[This corrects the article DOI: 10.1371/journal.pone.0243041.].
10.
Kim D, Lee J, Yun Kim H, Shin J, Kim K, Lee S, et al.
PLoS One
. 2020 Dec;
15(12):e0243041.
PMID: 33362250
Alzheimer disease (AD) is a neurodegenerative disorder characterized by the aberrant production and accumulation of amyloid-β (Aβ) peptides in the brain. Accumulated Aβ in soluble oligomer and insoluble plaque forms...